
|Articles|October 6, 2021
Syneos Health Acquires RxDataScience
Advertisement
Syneos Health has announced the acquisition of RxDataScience, a healthcare-focused data analytics, data management and artificial intelligence company.
RxDataScience’s product lifecycle solutions include scientific computing for R&D, patient journey, decentralized trials, RWE, predictive analytics and commercial market research. Additionally, RxDataScience offers a consulting-based model providing an iterative approach to develop and deliver analytics solution prototypes in six-to-eight-week sprints.
RxDataScience further scales Syneos Health’s data science abilities, adding capabilities and knowledge in data engineering and management. RxDataScience will be part of the Syneos Health Dynamic Assembly network.
Advertisement
Related to this article

Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions, while AI can prepare patients beforehand and support them afterward.

In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes, easing a clinical research workforce under strain.

In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, describes how physician awareness and site-level access drive screening inconsistencies, and why acceptance rates are the same across backgrounds once patients are simply asked.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Helps in Patient Conversations About Trials and Where Humans Must Lead
2
Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening
3
How AI-Enabled Trial Matching Is Changing Who Gets Identified and Screened
4
Measuring Burden Before It Becomes Risk: Coordinator Friction, Tool Fatigue, and Trial Quality
5

